StockNews.com Begins Coverage on Organovo (NASDAQ:ONVO)

Research analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a note issued to investors on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

ONVO stock opened at $0.31 on Wednesday. The stock has a market capitalization of $5.26 million, a P/E ratio of -0.36 and a beta of 0.45. Organovo has a one year low of $0.25 and a one year high of $1.83. The company has a 50 day moving average price of $0.43 and a two-hundred day moving average price of $0.44.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.02. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Research analysts forecast that Organovo will post -0.77 earnings per share for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.